Life Sciences partner Sophie McGrath and associate Kesten Laverty explain that women’s health and wellness industry has expanded exponentially over the last few years. Read the Maddyness UK article here.
Related Content
- Big Molecule WatchMay 16, 2025
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI (ustekinumab-aekn) with STELARA (ustekinumab)
- Big Molecule WatchMay 16, 2025
Join Us! The Future of Biotech Regulation Webinar
- Big Molecule WatchMay 15, 2025
Third Circuit Affirms Rejection of AstraZeneca’s Challenges to IRA Drug Price Negotiation Program
- Big Molecule WatchMay 15, 2025
President Trump Issues Two Executive Orders Concerning the Affordability and Accessibility of Drugs
- Life Sciences PerspectivesMay 14, 2025
Antitrust Life Sciences Quarterly Update 2025 Q1
- Life Sciences PerspectivesMay 13, 2025
Most Favored Nation Drug Pricing Executive Order Resurrects Prior President Trump Policy
- InsightMay 13, 2025
Antitrust Life Sciences Quarterly Update 2025 Q1
- AlertMay 12, 2025
Most Favored Nation Drug Pricing Executive Order Resurrects Prior President Trump Policy
- Press ReleaseMay 19, 2025
Goodwin Represents Inozyme Pharma in $270 Million Acquisition by BioMarin to Strengthen Enzyme Therapy Business
- Press ReleaseMay 12, 2025
Goodwin Scales Life Sciences Practice in Boston with the Arrival of Partner Felipe Heiderich
- In the PressMay 6, 2025
Rare Disease Industry Awaits FDA Chief’s New Drug Pathway Plan (Bloomberg Law)
- In the PressMay 1, 2025
AI in Healthcare: Private Equity’s Next Frontier? (Real Deals)
- Press ReleaseMay 1, 2025
Kronos Bio To Be Taken Private by Concentra Biosciences
- Press ReleaseMay 1, 2025
Goodwin Welcomes Leading Life Sciences and Intellectual Property Partner William T. Christiansen II Ph.D.
- Press ReleaseMay 1, 2025
Goodwin Guides Apnimed in Acquisition of Global Rights to Patents Covering Sulthiame, a Differentiated Carbonic Anhydrase Inhibitor
- Press ReleaseMay 1, 2025
Goodwin Guides Oak Hill Bio in Exclusive Licensing Agreement with Roche to Obtain Global Rights for a Treatment for Individuals with Angelman Syndrome